Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Dr. Benson on Challenges of Active Surveillance for Prostate Cancer

Dr. Benson on Challenges of Active Surveillance for Prostate Cancer

March 16th 2015

Mitchell Benson, MD, the Herbert and Florence Irving Professor at Columbia University Medical Center, New York-Presbyterian Hospital, discusses potential issues with active surveillance for patients with intermediate-risk prostate cancer.

Dr. Dreicer on Sequencing Therapies for Patients with Prostate Cancer

Dr. Dreicer on Sequencing Therapies for Patients with Prostate Cancer

March 16th 2015

Robert Dreicer, MD, MS, FACP, FASCO, Division of Hematology and Oncology, Department of Medicine, University of Virginia School of Medicine, discusses sequencing therapies in prostate cancer.

PD-1 Pathway Combos Lead the Way in RCC Immunotherapy

PD-1 Pathway Combos Lead the Way in RCC Immunotherapy

March 16th 2015

The prospects for combining anti–PD-1 pathway agents with other checkpoint blockade inhibitors or with agents that target angiogenesis are among the most promising immunotherapy approaches under development for patients with metastatic renal cell carcinoma.

Dr. Higano on Radium-223 for mCRPC

Dr. Higano on Radium-223 for mCRPC

March 16th 2015

Celestia S. Higano, MD, FACP, professor of medicine and urology, University of Washington, discusses radium-223 chloride and its efficacy for patients with metastatic castration-resistant prostate cancer (mCRPC).

Making Sense of the Prostate Cancer Screening Debate

Making Sense of the Prostate Cancer Screening Debate

March 14th 2015

Leonard G. Gomella, MD, told attendees at the 8th Annual IPCC that the decision to screen or not to screen for prostate cancer boiled down to "using common sense, shared decision making, and choosing the right patients to screen."

Proceed With Caution Is the Message on Active Surveillance

Proceed With Caution Is the Message on Active Surveillance

March 14th 2015

Physicians should engage in careful patient selection before recommending active surveillance for prostate cancer, according to Mitchell C. Benson, MD.

Noted Astronaut Addresses Importance of Teamwork at Prostate Congress

Noted Astronaut Addresses Importance of Teamwork at Prostate Congress

March 14th 2015

In a similar fashion as astronauts, physicians can mitigate risks and improve outcomes with advanced planning and teamwork, four-time space shuttle commander Tom Henricks said during his keynote address at the Interdisciplinary Prostate Cancer Congress.

Dr. Richard Stock on Brachytherapy for Prostate Cancer

Dr. Richard Stock on Brachytherapy for Prostate Cancer

March 14th 2015

Richard Stock, MD, a professor of radiation oncology at the Icahn School of Medicine at Mount Sinai Hospital, talks about brachytherapy and its benefits for patients with prostate cancer.

Dr. Petrylak on Immunotherapy for Second-line Treatment in Bladder Cancer

Dr. Petrylak on Immunotherapy for Second-line Treatment in Bladder Cancer

March 14th 2015

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center discusses the potential for immunotherapy for the treatment of bladder cancer.

Dr. Scholz on Using Abiraterone in mCRPC

Dr. Scholz on Using Abiraterone in mCRPC

March 4th 2015

Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the final analysis of the COU-AA-302 study, which compared abiraterone acetate to prednisone alone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dixon Questions Value of Chemoprevention With Tamoxifen

Dixon Questions Value of Chemoprevention With Tamoxifen

March 3rd 2015

The reduction of breast cancer risk with 5 years of tamoxifen does not outweigh the lack of a mortality benefit, according to J. Michael Dixon, MD, OBE, who shared his view in a session at the 32nd Annual Miami Breast Cancer Conference.

The Doctor Will Tweet With You Now: Social Media for Oncologists

The Doctor Will Tweet With You Now: Social Media for Oncologists

March 3rd 2015

Deanna J. Attai, MD, FACS, who interacts with her thousands of followers on Twitter, Facebook, YouTube, her blog, and other social media platforms, recently educated other physicians on what their role can be on social media.

Dr. Haas on Adjuvant Sorafenib or Sunitinib for RCC

Dr. Haas on Adjuvant Sorafenib or Sunitinib for RCC

March 2nd 2015

Naomi B. Haas, MD, associate professor, Abramson Cancer Center of the University of Pennsylvania, discusses the phase III ASSURE trial which looks at sorafenib or sunitinib for locally advanced renal cell carcinoma (RCC).

Dr. Siddiqui on Likely Candidates to Develop Prostate Cancer

Dr. Siddiqui on Likely Candidates to Develop Prostate Cancer

March 2nd 2015

Mohummad Minhaj Siddiqui, MD, assistant professor of surgery, University of Maryland School of Medicine, director of urologic robotic surgery, University of Maryland Marlene and Stewart Greenebaum Cancer Center, discusses a study which demonstrated men with testicular cancer are more likely to develop prostate cancer.

Top MBCC Abstracts Focus on Tumor Profiling and Radiotherapy Paradigms

Top MBCC Abstracts Focus on Tumor Profiling and Radiotherapy Paradigms

March 2nd 2015

A detailed tumor profile of molecular and protein alterations in a rare breast cancer subtype and a retrospective analysis about the impact of radiation after breast conserving surgery took home top honors at the Miami Breast Cancer Conference this year.

Targeted-Chemo Combination Active In Sarcomatoid, High-Risk RCC

Targeted-Chemo Combination Active In Sarcomatoid, High-Risk RCC

March 2nd 2015

A fourth of patients with sarcomatoid or poor-risk metastatic renal-cell carcinoma responded to treatment with the combination of sunitinib and gemcitabine.

US Lags in Adopting Hypofractionated Radiation Standard

US Lags in Adopting Hypofractionated Radiation Standard

March 2nd 2015

Compelling clinical trial evidence supports the use of hypofractionated radiation as the standard of care for postmenopausal women with luminal A tumors and node-negative disease.

Adding Anti-PD-L1 Antibody to Bevacizumab Induces Responses in mRCC

Adding Anti-PD-L1 Antibody to Bevacizumab Induces Responses in mRCC

March 2nd 2015

An investigational antibody that targets programmed death-ligand 1 (PD-L1) in combination with bevacizumab had strong antitumor activity and induced responses in 4 of 10 patients with metastatic renal cell carcinoma (mRCC) in an open-label phase Ib study.

Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast Cancer

Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast Cancer

February 28th 2015

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, goes over some of the challenges surrounding neoadjuvant treatment for HER2-positive breast cancer patients.

Dr. Muss on Optimizing Adjuvant Treatment for Older Breast Cancer Patients

Dr. Muss on Optimizing Adjuvant Treatment for Older Breast Cancer Patients

February 28th 2015

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses optimizing adjuvant treatment in older patients with breast cancer.

Joan Lunden Paints a Picture of Breast Cancer From the Patient's Perspective

Joan Lunden Paints a Picture of Breast Cancer From the Patient's Perspective

February 28th 2015

Joan Lunden presented the keynote address at the Miami Breast Cancer Conference where she spoke powerfully and from the heart in a talk perfectly aligned with the meeting's focus on the patient perspective.

Heterogeneity Complicates Treatment Decisions in Breast Cancer

Heterogeneity Complicates Treatment Decisions in Breast Cancer

February 28th 2015

Heterogeneity, which can result in treatment resistance, is commonly underestimated and misunderstood, representing an important area of future research.

Hudis Highlights Interplay Between Inflammation, Obesity, and Breast Cancer

Hudis Highlights Interplay Between Inflammation, Obesity, and Breast Cancer

February 28th 2015

In a discussion at the Miami Breast Cancer Conference, Clifford A. Hudis, MD, suggested that an increased risk for developing breast cancer might be a consequence of inflammation that often accompanies obesity.

Dr. Sledge on Using Tumor Heterogeneity to Guide Treatment in Breast Cancer

Dr. Sledge on Using Tumor Heterogeneity to Guide Treatment in Breast Cancer

February 28th 2015

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine, explains how tumor heterogeneity impacts patient care and research.

Second-Line Ramucirumab Plus Docetaxel in Urothelial Cancer Improves Progression-Free Survival

Second-Line Ramucirumab Plus Docetaxel in Urothelial Cancer Improves Progression-Free Survival

February 28th 2015

Ramucirumab added to docetaxel significantly improved PFS compared with docetaxel monotherapy as second-line treatment in a phase II study of patients with metastatic transitional cell carcinoma.

Dr. Carey on Treating Triple-Negative Breast Cancer

Dr. Carey on Treating Triple-Negative Breast Cancer

February 28th 2015

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Dr. Ryan on the Long Term Safety of Abiraterone Use

Dr. Ryan on the Long Term Safety of Abiraterone Use

February 27th 2015

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the final analysis of COU-AA-302.

Early Intervention Essential for Proper Lymphedema Management

Early Intervention Essential for Proper Lymphedema Management

February 27th 2015

Moving early to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming more severe.

Dr. Emmanuel Antonarakis on AR-V7 and Response to Taxanes in mCRPC

Dr. Emmanuel Antonarakis on AR-V7 and Response to Taxanes in mCRPC

February 27th 2015

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses a study looking at androgen receptor splice variant 7 (AR-V7) in metastatic castration-resistant prostate cancer (mCRPC).